Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for AC Immune (ACIU) over the last 11 years, with Dec 2024 value amounting to -$1.3 million.

  • AC Immune's Cash from Financing Activities fell 375.17% to -$948,806 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 103.89%. This contributed to the annual value of -$1.3 million for FY2024, which is 102.62% down from last year.
  • AC Immune's Cash from Financing Activities amounted to -$1.3 million in FY2024, which was down 102.62% from $48.8 million recorded in FY2023.
  • AC Immune's Cash from Financing Activities' 5-year high stood at $48.8 million during FY2023, with a 5-year trough of -$1.4 million in FY2022.
  • Over the past 3 years, AC Immune's median Cash from Financing Activities value was -$1.3 million (recorded in 2024), while the average stood at $15.4 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 5,120.06% in 2021, then plummeted by 103.13% in 2022.
  • Yearly analysis of 5 years shows AC Immune's Cash from Financing Activities stood at -$888,243 in 2020, then skyrocketed by 5,120.06% to $44.6 million in 2021, then plummeted by 103.13% to -$1.4 million in 2022, then soared by 3,589.76% to $48.8 million in 2023, then slumped by 102.62% to -$1.3 million in 2024.